Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Aclaris Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get ACRS alerts

About Hugh Davis

Hugh Davis is recorded as Board Member at Aclaris Therapeutics, Inc. (ACRS) since November 18, 2024 and COO at Aclaris Therapeutics, Inc. (ACRS). The newest filing on record that lists Hugh Davis as COO at Aclaris Therapeutics, Inc. (ACRS) is dated April 23, 2026. Aclaris Therapeutics, Inc. reported in an 8-K filed November 18, 2024 that Hugh Davis was appointed President and Chief Operating Officer. Aclaris Therapeutics, Inc. reported in an 8-K filed November 18, 2024 that Hugh Davis was appointed Class III director, effective November 18, 2024. Aclaris Therapeutics, Inc. reported in an 8-K filed November 18, 2024 that Hugh Davis was appointed President and Chief Operating Officer, effective November 18, 2024. Hugh Davis has spoken on 1 investor event across 1 company, most recently for Aclaris Therapeutics, Inc. on April 14, 2026. Aclaris Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Aclaris Therapeutics, Inc. includes Neal Walker (CEO, Chairman and Board Member), Kevin Balthaser (CFO), Douglas Manion (COO and Board Member) and 4 others.

“Hugh Davis, Ph.D., joins as President and Chief Operating Officer, bringing over 35 years of experience in biologics development, clinical pharmacology, and business development from leadership roles at Biosion, Frontage, GSK, and Johnson & Johnson.”
Aclaris Therapeutics, Inc. Form 8-K, filed November 18, 2024 · Read the filing
“The Board also appointed Dr. Davis to the Board, effective November 18, 2024, to serve as a Class III director to hold office until the 2027 annual meeting of stockholders and until his successor is duly elected and qualified, or his earlier death, resignation or removal.”
Aclaris Therapeutics, Inc. Form 8-K, filed November 18, 2024 · Read the filing

Hugh Davis on recent calls

“So yeah, as you pointed out, We think it's a best-in-class approach because not only do we have a T-slip antibody that is a very long retention time with the best potency in the class that we tested against other candidates and 70 times more potent than tezopelumab, and on the IL-4R side, the reason that was chosen in…”
COO, H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference ·

Affiliation history

Company network

Leadership on record at Aclaris Therapeutics, Inc.

Recent activity